Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer
Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic breast cancer by more than six months compared to women treated with a standard therapy of anastrozole alone (47.7 months vs 41.3 months).
The combination therapy also lengthened the median time to disease progression for these patients (15 months vs 13.5 months). Progression-free survival time was the primary endpoint measured in the trial; overall survival time was a secondary endpoint.
"The combination offers a new standard for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer," says lead investigator on the study Rita Mehta, M.D., of the University of California, Irvine Medical Center. "It has been many years since these patients have seen a new treatment that can significantly extend their overall survival time."
Anastrozole (Arimidex) and fulvestrant (Faslodex), the anti-estrogen drugs included in the SWOG S0226 trial, are both already used in treating breast cancer, though not in combination. Anastrozole suppresses the body's production of tumor-promoting estrogen, while fulvestrant not only blocks the receptors that estrogen uses to drive tumor cells to grow and reproduce, but also accelerates the degradation of these receptors. Mehta and her colleagues hypothesized that these two different modes of action together could make the combination more effective than either alone against hormone receptor-positive breast cancer, the subtype seen in more than one half of all cases of breast cancer.
The paper also reports that 41 percent of patients on the anastrozole-only arm switched to fulvestrant treatment after their disease progressed on anastrozole, suggesting that combined use of the two agents rather than the sequential use underlies the impressive survival benefit seen in the study.
Earlier results of the trial, which enrolled 707 postmenopausal breast cancer patients at 73 U.S. institutions, were presented at a professional meeting in December 2012. The New England Journal of Medicine article reports additional data.
The researchers note that they saw improvement in survival in spite of the fact that the dose of fulvestrant used in the trial 250 mg monthly was only half of what the accepted standard is today, and in spite of the fact that the control arm performed better than projected in the design of the study. They recommend that future clinical trials compare the combination of high-dose fulvestrant and an aromatase inhibitor such as anastrozole against each of the drugs alone.